Association of metformin treatment and outcome in adult patients with ITP and pre-existing T2DM.

Abstract

Primary immune thrombocytopenia (ITP) is an autoimmune haemorrhagic disease that could manifest with comorbid type 2 diabetes mellitus (T2DM). However, the exact impact of T2DM in patients with ITP remains uncertain. In this study, we performed a retrospective cohort study of 458 participants with ITP. The prevalence of T2DM was 7.6% in this population (35 patients), which was slightly lower than the Chinese nationwide prevalence of T2DM, calculated to be approximately 10.9%. The participants with pre-existing T2DM displayed a significantly higher response to therapy than those without T2DM (71% vs. 53%). Furthermore, in the T2DM cohort, the response rate reached 88% when metformin was included in the treatment regimen. This clinical evidence suggests that metformin therapy might improve the clinical outcomes of ITP.

• Authors: Chaoyang Li, Meng Sun, Ranran Li, Shuwen Wang, Linlin Shao, Miao Xu, Meiyue Yao, Lin Wang, Ming Hou, Qi Feng, Jun Peng
• Journal: British journal of haematology (Br J Haematol) Vol. 197 Issue 3 Pg. 367-372 (05 2022) ISSN: 1365-2141 [Electronic] England
• PMID: 35288929 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 British Society for Haematology and John Wiley & Sons Ltd.

Chemical References

• Hypoglycemic Agents
• Metformin

Topics

• Adult
• Diabetes Mellitus, Type 2 (complications, drug therapy, epidemiology)
• Humans
• Hypoglycemic Agents (therapeutic use)
• Metformin (therapeutic use)
• Retrospective Studies
• Treatment Outcome